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Abstract  
Purpose The aim of this study was to compare conventional medical follow-up with follow-up containing 
additional nursing consultations regarding the psychosocial adjustment and health related quality of life 
(HRQOL) of head and neck cancer patients.  
Methods Using a quasi-experimental design, patients were enrolled consecutively into two groups. Experimental 
care covered six 30-minute bimonthly nursing follow-up consultations during the first year posttreatment. Data 
were collected at posttreatment months 1 (baseline), 6 and 12 for both groups. 
Results The intervention group was significantly worse at baseline, based on two of the seven adjustment scales 
and on the majority of HRQOL scales. However, their outcome at 6 and 12 months was consistent with that of 
the group which received conventional follow-up. Thus, the intervention group had a larger improvement in 
scores, and this was significant for one of the seven adjustment scales and 19 of the HRQOL scales at 6 and 12 
months, respectively. Most of the differences in HRQOL scales were clinically relevant at 6 months.  
Conclusion These results suggest that nurse-led consultations for patients with head and neck cancer have a 
positive effect, primarily with respect to HRQOL. Nurse-led follow-up leads to a similar psychosocial 
adjustment as conventional follow-up, even among patients who showed worse performance at the start of 
follow-up. Thus, nurse-led follow-up may be a cost-effective way to improve follow-up care for this patient 
group. 
Trial registration Clinicaltrials.gov (NCT01167179) 
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Introduction  
 
It is generally accepted that regular posttreatment surveillance is important for the general well-being of cancer 
patients, for the management of (late) complications, and for detecting recurrence of cancer in an asymptomatic 
stage. 
1
 It is also recognized that long-term routine follow-up in head and neck cancer (HNC) patients does not 
lead to improved survival and is inefficient at detecting recurrence. 
2-4
 For HNC patients, a rigid one-size-fits-all 
approach of follow-up is questionable, and there is currently an ongoing professional debate to determine the 
optimum duration and content of follow-up care. 
4
 However, other goals of follow-up care, (e.g., management of 
(late) complications, evaluation of treatment and psychosocial care) remain crucial and are being increasingly 
recognized as an important standard of care for cancer management. 
1
 
Specialized nurses are frequently considered as the appropriate professionals for assuming a role in cancer 
follow-up. 
5-7
 With regard to cancer populations such as breast, lung, prostate, colorectal and oesophageal cancer 
patients, nurse-led care has been found to be acceptable, appropriate and effective, and does not adversely affect 
patient quality of life compared with standard follow-up care by clinicians. 
8-12
 In a study of nurse-led follow-up 
for HNC patients undergoing radiotherapy, positive effects were found with respect to attendance at follow-up 
visits and no differences regarding health related quality of life (HRQOL) scores compared with physician 
appointments. 
6
 
In recent years, the Head and Neck Oncology Centre at our institute tested an integrated care program for 
HNC patients. The results suggested improvement, particularly with respect to information and psychosocial 
support. 
13
 Upon confirming the results by interviews with 21 HNC patients regarding the management of their 
discharge advice and posttreatment care, it was decided to start the current study. 
14
  
In this trial, we compared predominantly medically oriented follow-up (i.e., conventional care) with 
follow-up that was expanded using structured nursing consultations (i.e., experimental care), focusing on 
supportive care and simple medical control checks. We hypothesized that the experimental care would result in 
improved patient outcomes on psychosocial adjustment and HRQOL relative to conventional care.  
 
Materials and methods  
 
Study design and setting 
 
This quasi-experimental prospective single-center study was conducted at the Radboud University Center for 
Oncology in Nijmegen, the Netherlands. The study was a full-scale pilot in accordance with the guidelines of the 
Medical Research Council (MRC) Framework for the Evaluation of Complex Interventions. 
15, 16
 A comparison 
group (n=80) and (after providing a training for nurses) an intervention group (n=80) were recruited 
consecutively. Ethical approval was obtained from the regional Medical Ethical Committee (CMO-nr. 
2007/113), and the study was conducted in accordance with the Declaration of Helsinki. 
17, 18
  
 
Participants 
 
The eligibility criteria for the study were as follows: informed of a HNC diagnosis (but no other cancer); to be 
treated with curative intent; to be able to speak, write and understand Dutch; and be cognitively able to provide 
informed consent. Exclusion criteria included overt psychopathology, alcohol addiction, and/or a life expectancy 
of less than 6 months. HNC patients who attended a weekly screening session were identified and approached by 
oncology nurses. For this purpose, the nurses used a written scenario. All participants provided a written 
informed consent. Patients were recruited to the comparison and intervention groups from November 2007 to 
July 2008 and from January 2009 to February 2010, respectively. A total of 170 eligible patients were asked to 
participate. Ten patients refused: six were not willing to participate, two preferred physician follow-up only, and 
two declined for other reasons. 
The nurse participants were registered nurses currently working as legal registered oncology nurses. All of 
the nurses were female, (mean age 43 years) with a mean experience in the HNO field of 11 years (range 6-20 
years). Nurses were eligible if they had indicated a willingness to receive training and supervision and to have 
their performance evaluated on a regular basis. 
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 One nurse unexpectedly withdrew from the study. A new nurse was recruited and individually trained 
and instructed by the researcher. Subsequently, this nurse participated in the supervision, coaching and video 
recording as planned. To compensate for this delay, the recruitment period for the intervention group was 
extended by 2 months. 
 
Procedure 
 
Conventional care 
 
The participants in the comparison group received conventional care that consisted of a 5-year routine control 
schedule with six bimonthly 10-minute visits to a head and neck surgeon in the first year posttreatment in 
accordance with national guidelines. 
19
 Nursing follow-up care consisted of ad hoc problem-based contacts 
except for patients who underwent a laryngectomy, who received standard nursing consultations during the first 
6 months posttreatment in parallel with the medical control visits. Patients who were treated with surgery alone 
all had one standard wound control visit with a nurse; patients who were treated with radiotherapy had one to six 
ad hoc nursing contacts during the first 6 months posttreatment. For the duration of the study, there were no 
changes in conventional care. 
 
Experimental care 
 
The intervention consisted of six 30-minute nursing follow-up consultations in the first year posttreatment. A 
standardized protocol was used for this purpose. Nursing consultations were conducted in parallel with and 
preceding the medical routine control visits and included a needs assessment based upon the biopsychosocial 
model. 
20
 The aim of consultation was to give advice and support to patients (and their partners) addressing the 
physical and psychosocial consequences of treatment. To increase patient focus and active participation during 
consultations, patients completed a 13-item checklist prior to each consultation. 
14, 21-23
 Every 3 months, patients 
were screened for psychosocial problem areas using a specific questionnaire. 
24
 
During the consultations, the nurses also performed simple medical checks including inspection of the 
tracheal stoma, cannula and speech valve (if applicable), and oral cavity, and palpation of the neck and lymph 
nodes. 
 
Training of nurses 
 
Before recruiting patients to the intervention group, nurses participated in two 3-hour training sessions for the 
following items: 1) information regarding the biopsychosocial model and 2) performing a consultation using 
exploratory communication skills. Training sessions were developed and delivered in collaboration with a 
clinical psychologist (author J.P.). Also, two head and neck surgeons delivered a 2-hour training session 
regarding how to perform simple medical checks. During the intervention period, nursing supervision meetings 
were planned every 2 months led by a clinical psychologist (J.P.). The aims were to share experiences from 
consultations, provide collegiate support, and address issues that obstructed execution of the intervention. 
Individual coaching of nurses was offered by the researcher by attending several consultations followed by 
reflective conversations afterwards.  
 
Outcome measures 
 
The primary outcomes were psychosocial adjustment and HRQOL. Psychosocial adjustment can be viewed as 
“the adaptive psychosocial response of an individual to a significant life change” 25 and was assessed using the 
Psychosocial Adjustment to Illness Scale – Self Report (PAIS-SR), a 46-item self-report measure that assesses 
changes in seven domains. A mean PAIS-SR T-score of 50 is the average score for each domain, meaning that 
patients with this score adjusted neither better nor worse than a mixed cancer reference group, whereas a score 
lower than 50 indicates better adjustment. The PAIS-SR is well validated and has been used in previous studies 
of HNC patients. 
26-28
 Here, we used the validated Dutch translation. 
29
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HRQOL can be defined as; “a state of physical, mental and social well-being and not merely absence of 
disease or infirmity”. 30 HRQOL was measured with the European Organisation of Research and Treatment of 
Cancer Quality of Life Questionnaire with additional Head & Neck Module (EORTC QLQ-C30 and QLQ-
H&N35). 
31, 32
 These are cancer-specific patient-based self-report questionnaires, and the psychometric 
properties of both have been tested thoroughly in several studies. 
33, 34
 The core questionnaire was composed of 
five functioning scales, a global health status/QOL scale, and nine symptom scales. The additional H&N35 
module contained 18 disease-specific symptom scales. All EORTC scores were transformed to a 0-100 scale in 
accordance with the procedures in the scoring manual. 
32
 A high score for the functional scales and for the global 
health status/QOL scale represents a high level of functioning, whereas a high score on a symptom scale 
represents a high level of symptoms.  
 
Data collection  
 
Data were collected from November 2007 to March 2011. Patient demographic and disease-related 
characteristics were retrieved from patient records. Questionnaires were delivered 1, 6 and 12 months after 
treatment. The baseline moment of the 1-month posttreatment questionnaire was set to a week before the first 
nursing consultation. To increase patient compliance in returning questionnaires several steps were taken, 
including postage-paid return envelopes, a postal reminder after one month, and, if necessary, a repeat postal 
reminder 1 month later together with a new set of questionnaires.  
 
Statistical analysis 
 
SPSS 18.0 was used to analyze the descriptive data. Baseline differences between groups with respect to 
sociodemographic and disease characteristics were tested using 2 test. Data were analyzed on an intention-to-
treat basis. To account for the similarity of each measurement within patients, a linear mixed model for repeated 
measurements was applied to analyze the effect of nurse-led follow-up consultations on the primary outcome 
variables. These models also account for missing data (provided that the missing data were missing at random). 
The SAS software package (version 8.2) was used to fit the models. Intervention and time (as well as their 
interaction) and the adjustment factors tumor location, size of the tumor (stage I, II vs. stage III, IV), treatment 
modality, living without a partner, and education (high vs. other) were included in the model as fixed effects. 
Differences between groups at baseline, 6, and 12 months, and differences in change from baseline to 6 and 12 
months were estimated from this model. An unstructured covariance matrix was fitted. 
To facilitate the interpretation of scores of differences in changes from baseline, the frequency of clinically 
relevant changes was analyzed. A clinically relevant change in PAIS-SR was defined as a change of 1 standard 
deviation (10 units) in mean T-score compared to the preceding measurement. 
26
 For the EORTC, a clinically 
relevant change was defined as change of 10 points in mean scores. 
35
   
No formal power calculation was performed, as this study was an exploratory trial. The sample size was 
determined by taking into consideration the number of patients lost due to recurrence of cancer and/or death.  
 
Treatment fidelity 
 
Several measures were taken to strengthen treatment fidelity in this study. 
36
 All of the nurses had similar levels 
of education, which is relevant when group training is provided. During training, standardized materials and role 
playing were used. To minimize the drift of skills after training, supervision meetings and individual coaching 
sessions were offered for the duration of the intervention period. To help the nurses and to improve delivery of 
the intervention as intended, we used a standardized consultation protocol. Additionally, video recordings of 
consultations were used to verify the actual professional performance (results will be reported elsewhere), and 
the researcher maintained contact with nurses several times per week to monitor intervention delivery, and to 
serve as a consultant.  
 
Results  
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Demographic and disease characteristics are shown in Table 1. Both, educational level and treatment modality 
differed significantly between groups. No explanation other than coincidence was found to account for the 
difference in educational level. During the recruitment period of the intervention group, there was an increase in 
chemoradiation treatment for patients with stage III or IV malignancies. Consequently, more patients in the 
intervention group received this treatment, and this accounts for the difference in treatment modality between 
groups.  
 
Response rate  
 
At 12 months, 124 patients (78%) had returned their mailed questionnaires. The reasons for nonresponse were 
distributed as follows for the intervention and comparison groups, respectively: recurrence of disease, 4/4; death, 
10/4; withdrawal from study, 2/1; other reasons, 5/6 patients. The number of non-responses was distributed 
evenly between the groups at 6 and at 12 months, with the exception of “death” (at 6 months, eight and two 
patients had died in the intervention and comparison groups, respectively). 
 
Psychosocial Adjustment 
 
The baseline mean scores for the PAIS-SR (Table 2) were significantly worse in the intervention group for the 
domains of health care orientation, social environment and total adjustment (p =<0.05). At 6 months, no 
significant differences were observed between groups; at 12 months, health care orientation differed significantly 
between groups (p=<0.02), although the difference never exceeded 1 standard deviation. Table 4 shows the 
results from the mixed model analysis. No significant difference between groups was detected in the change 
from baseline in PAIS-SR scores at 6 and 12 months, with the exception of the domain of social environment, in 
which the intervention group had significant worse scores at baseline (p=<0.05) but a 7.8-point (95%-CI=2.3, 
13.2) and 6.7-point (95%-CI=1.3, 12.2) larger improvement than the comparison group at 6 and 12 months, 
respectively.  
Analyses of clinically relevant changes are presented in Table 5. Nearly equal numbers of patients in both 
groups had improved by at least 1 standard deviation at 6 and 12 months. With respect to deterioration, however, 
at 6 months, more patients had deteriorated in the intervention group than in the comparison group. The largest 
difference was in the domain of social environment, with twice as many deteriorated patients in the intervention 
group as in the comparison group (27 vs. 13 patients, respectively). At 12 months, the number of deteriorated 
patients was approximately equal between groups. 
 
Health Related Quality of Life 
 
For most of the EORTC scales, baseline mean scores were significantly worse (p=<0.05) for the intervention 
group (Table 2). At 6 and 12 months, the mean scores were not significantly different between groups. At 6 and 
12 months, differences in scores with respect to changes from baseline were significantly larger for the 
intervention group for many of the EORTC scales (Table 4). This was the case for 3 of the 5 functional scales, 
for global health status/QOL, for 6 of the 9 generic symptom scales, and 9 of the 18 specific head and neck 
scales at each time point. The most robust clinically relevant changes (i.e., a change of 10 points or more on a 
given scale) occurred at 6 months (see Table 5). For many items, more patients improved in the intervention 
group than in the comparison group. A difference of 10 patients or more (in favor of the intervention group) was 
observed for 3 of the 5 functional scales, for global health status/QOL, for 3 of the 9 generic symptom scales, 
and for 11 of the 18 specific head and neck scales. The largest difference between groups was seen with respect 
to fatigue at 6 months and for pain and social eating at 12 months, both differences favoring the intervention 
group.  
 
Aspects of treatment fidelity 
 
To determine to which extent the intervention was executed as planned, several aspects were evaluated. Patient 
participation in nursing follow-up consultations was deemed to be good; 480 consultations were planned, and 
389 (81%) were realized. In addition, 70% (n=56) of the patients attended all consultation sessions. The reasons 
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for failing to attend a consultation included: recurrence of disease and/or death (n=14), planning errors (n=5), 
withdrawal from study (n=2), and other causes (n=3). In 49% (189) of consultations nurses independently 
performed medical checks, 154 of which were verified by a physician (Table 3). In 37% (145) of the 
consultations, the nurses did not execute medical checks, but rather asked a physician for this task. This latter 
group of consultations was for laryngeal patients, as the required laryngoscopy had to be performed by a 
physician: thus, to minimize patient burden, nurses asked the physician to perform the other medical control 
checks as well. In 14% (55) of the nursing consultations, it was unclear whether (and how) medical checks were 
performed, as registration information was missing. The nurses themselves reported that the majority of 
consultations could be performed adequately within 30 minutes, and they reported an increase in work 
satisfaction, as they were now (in their words) “finally doing what I’m trained for”. 
 
Discussion  
 
Cancer follow-up is shifting slowly from the detection of recurrence towards the management of several aspects 
of cancer survivorship. Specialized oncology nurses are increasingly embedded in a multidisciplinary cancer 
care team to provide symptom management and supportive follow-up care. Several reviews have suggested that 
this care has the potential to add quality to cancer care and decrease costs; however, there is currently a paucity 
of sound economic evaluation research. 
37, 38
 Substituting nurses for doctors is a potential next step in cancer 
care, but additional research is needed before nurse-led follow-up care can be considered equivalent to 
physician-led follow-up care in terms of survival, recurrence, and cost-effectiveness. Patient perspective with 
respect to follow-up care seems to be shifting as well. In a recent survey in the UK, when 263 HNC patients 
were asked, “who they would like to contact in a system based on patient-reporting problems and requesting 
appointments,” 45% (118 patients) stated a preference for a clinical nurse specialist. 39  
The results of our study show that nurse-led follow-up had positive effects on HRQOL, although effects were 
small and were not statistically significant. In the intervention group, in patients who were initially worse at 
baseline, psychosocial adjustment and HRQOL scores at 6 and 12 months reached same levels as in patients in 
the comparison group, which had received conventional care. Therefore, the differences in the changes in scores 
from baseline between groups were significantly larger for the intervention group, and this effect was primarily 
in the HRQOL scores. More clinically relevant changes were more observed in the intervention group at 6 
months for many of the disease-specific and generic HRQOL scores.  
Patients in both groups experienced few significant problems with psychosocial adjustment (PAIS-SR). In a 
study by Vickery et al., a total adjustment score at 6-18 months posttreatment of 47-51 was reported. 
28
 In both 
our study groups, scores were lower, suggesting improved overall adjustment. Greer et al. 
40
 applied the PAIS-
SR in a prospective design and tested a psychological therapy intervention in 174 patients, 9 of whom were HNC 
patients. In this randomized trial, no significant differences between groups persisted at the 4-month follow-up, 
with the exception of the domain of psychological distress. The mean total adjustment score in the experimental 
group was 50. At baseline (1 month post treatment), our intervention group reported minor disturbances in 
adjustment; therefore, possibilities for improvement were perhaps somewhat limited. The domain of health care 
orientation showed a small but significant difference in mean scores at 12 months in favor of the comparison 
group. This domain concerns the patient’s perspective regarding health and health care. No explanation for this 
difference can be given except perhaps increased “health care awareness” among patients in the intervention 
group as a result of nurse-patient conversations causing a slightly more critical score in this domain. Because we 
did not measure pretreatment scores, it is unclear whether (and to what extent) any psychosocial adjustment had 
occurred during the course of treatment. It would be interesting, however, to determine how adjustment scores in 
disease-free HNC patients will develop over the coming years. This is particular important for patients with a 
permanent impairment and/or long-term symptom burden.  
The EORTC questionnaire combined with the H&N35-module is a sensitive instrument for detecting 
differences in this patient population. The results of the HRQOL scores were more disparate than those of the 
PAIS-SR. Although there were no differences in mean scores between groups 6 or 12 months, clinically relevant 
changes were more prevalent in the intervention group, thereby supporting the results of the mixed model 
analyses. In agreement with other HNC studies, the largest improvement in HRQOL scores in both groups 
occurred in the first six months posttreatment. 
41, 42
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In considering these findings, it is important to acknowledge the study’s limitations. A key issue is the study 
design, which lacked randomization; thus, possible confounding factors may have influenced the results. The 
quasi-experimental design also limited the possibility of assessing causality. Due to practical and organizational 
limitations, conducting a randomized controlled trial was not feasible. Specifically, contamination was a 
potential problem, due to a small nursing staff (three nurses). Thus, a quasi-experiment (pre-test, post-test) with a 
historical control group was the best alternative.  
In conclusion, oncology nurses can contribute considerably to further development and advancement of 
follow-up care for HNC patients. Although our single institution setting and some methodological disadvantages 
limit the findings, our results imply potential value and suggest improved outcomes for HNC patients. The 
nurse-led model that we used can be readily modified for use in other (cancer) patient populations. Future 
research regarding nurse-led follow-up care for HNC patients should focus on improvement of the intervention 
program, and on continued evaluation of patient’s outcomes, including HRQOL. A possible multi center 
implementation study of this nurse-led program combined with a thorough economic evaluation would provide 
valuable additional information for cancer follow-up care.  
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Table 1 Demographic and disease characteristics per group 
 
 Intervention group 
(n=80)  
Comparison group 
(n=80)  
Gender   
Male  54 (67.5) 60 (75) 
Age, years   
Mean [range] 58.4 [22-86] 59.2 [30-83] 
Marital status   
Living with partner 56 (70.9) 58 (73.4) 
Occupational status   
Employed 52 (67.5) 43 (55.8) 
Educational level
a 
  
High 29 (36.3) 14 (18.2) 
 
Medium 19 (23.8) 22 (28.6) 
Low 32 (40.0) 41 (53.2) 
Caucasian race  79 80 
Cancer site   
Larynx 14 (17.5) 23 (28.8) 
Hypopharynx 7 (8.8) 1 (1.3) 
Oropharynx 15 (18.8) 10 (12.5) 
Oral cavity 32 (40.0) 34 (42.5) 
Other 10 (12.5) 10 (12.5) 
Stage (UICC – 2011)   
I 24 (30.0) 30 (37.5) 
II 19 (23.8) 22 (27.5) 
III 10 (12.5) 7 (8.8) 
IV 24 (30.0)
 
12 (15.0)
 
No stage 2 (2.5) 0 
Treatment modality
a 
  
Surgery only 34 (42.5) 50 (62.5) 
Surgery + Radiotherapy 11 (28.8) 9 (22.5) 
Radiotherapy alone 23 (13.8) 18 (11.3) 
Chemoradiation 12 (15.0)
 
1 (1.3)
 
Laser surgery 0 2 (2.5) 
Figures in parentheses are percentages 
a 
Significant difference between the groups (2 - test) 
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Table 2 Mean (SD) scores of PAIS-SR and EORTC QLQ-C30 / EORTC QLQ-H&N35 at baseline, 6 and 12 
months (n=160) 
 
 Baseline (SD) 6 months (SD) 12 months (SD) 
PAIS-SR 
a intervention 
group 
comparison 
group 
intervention 
group 
comparison 
group 
intervention 
group 
comparison 
group 
Health care orientation 54 (10) * 50 (8) 51 (8) 49 (9) 52 (9) * 48 (8) 
Vocational environment 62 (7)   59 (7) 57 (7) 56 (7) 54 (7) 54 (7) 
Domestic environment 46 (9)   44 (9) 43 (9) 42 (9) 42 (9) 41 (9) 
Sexual relations 49 (9) 47 (9) 46 (8) 47 (9) 46 (8) 47 (9) 
Extended family relations 49 (8) 50 (8) 49 (7) 52 (8) 49 (7) 49 (7) 
Social environment 51 (15) * 45 (15) 43 (15) 43 (13) 42 (14) 42 (13) 
Psychological distress 49 (10) 46 (10) 45 (10) 45 (10) 45 (11) 43 (10) 
Total adjustment 50  (11) * 46  (12) 44 (12) 44 (13) 43 (13) 42 (12) 
EORTC QLQ-C30             
Functional Scales 
b 
            
Physical functioning 71 (23) * 86 (17) 83 (17) 86 (16) 86 (17) 87 (16) 
Role functioning 54 (32) * 75 (27) 79 (26) 81 (24) 81 (27) 85 (25) 
Emotional functioning 80 (24) 83 (18) 84 (19) 85 (19) 82 (23) 85 (18) 
Cognitive functioning 81 (23) 87 (19) 88 (17) 87 (17) 87 (20) 86 (21) 
Social functioning 76 (25) * 88 (22) 91 (15) 90 (16) 90 (19) 91 (21) 
Global health status/QOL 64 (23) * 76 (17) 77 (16) 80 (18) 81 (18) 80 (17) 
Symptom scales 
c 
            
Fatigue 46 (29) * 29 (23) 24 (21) 25 (23) 19 (25) 22 (24) 
Nausea/vomiting 15 (29) * 7 (15) 3 (13) 4 (13) 3 (13) 4 (10) 
Pain 35 (29) * 18 (22) 15 (22) 14 (23) 12 (22) 15 (22) 
Dyspnea 19 (26) * 9 (18) 10 (20) 14 (23) 12 (21) 12 (19) 
Insomnia 29 (29) 23 (29) 20 (28) 18 (25) 19 (30) 18 (25) 
Appetite loss 29 (35) * 12 (24) 13 (23) 9 (19) 7 (17) 8 (21) 
Constipation 21 (30) * 10 (19) 8 (21) 6 (14) 7 (18) 6 (15) 
Diarrhea 10 (23) 7 (17) 5 (15) 6 (16) 4 (11) 8 (18) 
Financial difficulties 10 (25) 8 (15) 7 (17) 8 (20) 8 (22) 7 (15) 
EORTC QLQ-H&N35             
Symptom scales 
c 
            
Pain 38 (24) * 25 (22) 15 (16) 15 (14) 14 (17) 14 (18) 
Swallowing 37 (30) * 20 (21) 4 (18) 11 (16) 9 (19) 10 (15) 
Senses 29 (30) * 16 (20) 17 (24) 14 (21) 18 (26) 15 (23) 
Speech 29 (27) *  17 (20) 12 (21) 8 (15) 11 (19) 10 (19) 
Social eating 34 (27) * 16 (21) 15 (18) 9 (19) 10 (19) 9 (17) 
Social contact 12 (18) * 6 (11) 6 (10) 4 (9) 5 (12) 3 (8) 
Less sexuality 31 (35)  20 (29) 19 (26) 20 (29) 19 (27) 15 (23) 
Teeth problems 15 (28) 23 (31) 15 (28) 17 (27) 11 (24) 12 (24) 
Opening mouth 43 (35) * 24 (31) 17 (29) 14 (23) 11 (21) 10 (21) 
Dry mouth 47 (36) 44 (30) 41 (33) 38 (35) 38 (34) 33 (33) 
Sticky saliva 47 (38) * 33 (34) 34 (32) 23 (32) 25 (32) 22 (29) 
Coughing 33 (33) * 20 (26) 16 (23) 20 (30) 20 (26) 15 (25) 
Feeling ill 28 (33)  18 (26) 6 (17) 12 (24) 7 (22) 9 (18) 
Use of pain killers 63 (49) * 43 (50) 29 (46) 24 (43) 22 (42) 22 (42) 
Use of nutritional 
supplements 
44 (50) * 22 (42) 22 (42) 13 (34) 9 (28) 8 (27) 
Use of feeding tube 15 (36) 6 (24) 3 (18) 0 (0) 3 (18) 2 (12) 
Weight loss 56 (50) * 26 (44) 16 (37) 17 (38) 15 (36) 13 (33) 
Weight gain 13 (34) * 29 (46) 26 (44) 35 (48) 27 (45) 34 (48) 
‡ p<0.05 (significant at this level, t-test for independent samples) 
a PAIS-SR: Compared to a mixed cancer reference group, scores > or < 50 indicate worse or better adjustment, respectively 
b EORTC: Higher score, better functioning (range 0-100) 
c EORTC: Higher score, more symptoms (range 0-100) 
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Table 3 Medical control checks by nurses during nursing consultations (389 consultations) 
 
 laryngeal 
patients  
all other HNC 
patients  
 
no. (%) 
Independent    1  34 35 (9) 
Independent + checked by physician    5 149 154 (40) 
Not executed, and asked physician 145     0 145 (37) 
Missing (performance not registered)   42   13 55 (14) 
Total 193 196 389  
Figures are number of consultations. Figures between parentheses are percentages. 
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Table 4 Differences in change from baseline (i.e., 1 month after medical treatment) at 6 and at 12 months  
 
 Baseline 6 months 12 months 
 score  
(p value)a 
Change from baseline 
(95%CI)a 
p-value* Change from baseline 
(95%CI) a 
p-value* 
PAIS-SR        
Health care orientation   2.6 (0.12) -0.6 (-3.6,2.5) 0.71 0.0 (-3.1,3.2) 0.98 
Vocational environment   2.7 (0.03) -0.7 (-3.2,1.9) 0.59 -2.4 (-5.0,0.2) 0.07 
Domestic environment   2.8 (0.09) -1.8 (-4.7,1.2) 0.24 -2.4 (-5.4,0.6) 0.12 
Sexual relations   0.7 (0.65) -2.0 (-4.8,0.7) 0.15 -2.4 (-5.4,0.5) 0.11 
Extended family 
relations 
-1.0 (0.39) -0.6 (-3.5,2.1) 0.64 0.3 (-2.2,2.9) 0.80 
Social environment 5.1 (0.04) -7.8 (-13.2,-2.3) 0.01 -6.7 (-12.2,-1.3) 0.02 
Psychological distress 3.6 (0.07) -1.8 (-5.1,1.5) 0.29 -1.2 (-4.5,2.2) 0.49 
Total adjustment 3.3 (0.13) -3.6 (-7.5,0.4) 0.07 -3.5 (-7.5,0.6) 0.09 
EORTC QLQ-C30        
Functional Scales        
Physical functioning -13.1 (0.00) 11.3 (4.3,18.4) 0.00 12.7 (5.8,19.7) 0.00 
Role functioning -17.8 (0.00) 21.1 (9.8,32.5) 0.00 17.3 (4.1,30.4) 0.01 
Emotional functioning -5.6 (0.18)   1.0 (-5.8,7.7) 0.77 1.0 (-6.0,8.0) 0.78 
Cognitive functioning -5.2 (0.21)   4.4 (-2.7,11.4) 0.22 5.9 (-1.3,13.1) 0.11 
Social functioning -12.4 (0.01) 12.9 (4.9,21.0) 0.00 11.5 (1.9,21.0) 0.02 
Global health 
status/QOL 
-10.4 (0.00)   8.7 (1.1,16.3) 0.02 12.1 (4.6,19.7) 0.00 
Symptom scales        
Fatigue 15.5 (0.00) -17.6 (-26.8,-8.3) 0.00 -19.2 (-29.1,-9.3) 0.00 
Nausea/vomiting 9.3 (0.03)  -8.9 (-16.0,-1.9) 0.01 -10.3 (-17.9,-2.7) 0.01 
Pain 16.7 (0.00) -14.4 (-24.1,-4.7) 0.00 -17.9 (-27.7,-8.1) 0.00 
Dyspnea 9.7 (0.02) -15.2 (-24,-6.4) 0.00 -10.8 (-19.1,-2.5) 0.01 
Insomnia 5.2 (0.37)   -3.2 (-14.0,7.5) 0.55 -3.3 (-14.1,7.5) 0.55 
Appetite loss 12.8 (0.02) -10.4 (-20.6,-0.2) 0.04 -17.0 (-27.3,-6.7) 0.00 
Constipation 14.3 (0.00) -9.7 (-18.8,-0.7) 0.04 -12.2 (-21.2,-3.3) 0.01 
Diarrhea 2.5 (0.52)   -2.5 (-9.9,4.8) 0.50 -6.8 (-15.8,2.1) 0.13 
Financial difficulties 3.0 (0.43)   -2.9 (-10.3,4.4) 0.43 -1.5 (-0.9,6.3) 0.71 
EORTC QLQ-H&N35        
Symptom scales        
Pain 12.2 (0.01) -11.2 (-19.5,-3.0) 0.01 -13.1 (-22.5,-3.7) 0.01 
Swallowing 17.7 (0.00) -12.2 (-21.5,-2.8) 0.01 -18.3 (-27.1,-9.4) 0.00 
Senses 10.2 (0.02) -9.6 (-17.1,-2.1) 0.01 -11.5 (-20.1,2.8) 0.01 
Speech 13.3 (0.00) -4.6 (-12.3,3.1) 0.24 -10.1 (-18.6,-1.7) 0.02 
Social eating 17.1 (0.00) -10.9 (-19.0,-2.9) 0.01 -17.2 (-26.3,-8.2) 0.00 
Social contact 7.0 (0.02) -4.5 (-9.5,0.6) 0.09 -5.1 (-10.2,-0.1) 0.05 
Less sexuality 10.0 (0.09) -11.5 (-21.8,-1.3) 0.03 -8.8 (-20.7,3.2) 0.15 
Teeth problems -7.5 (0.19) 10.3 (-3.5,19.3) 0.17 10.2 (-0.9,21.4) 0.07 
Opening mouth 15.6 (0.01) -15.0 (-27.9,-2.2) 0.02 -18.4 (-30.6,-6.2) 0.00 
Dry mouth -2.0 (0.75) 0.4 (-8.8,9.5) 0.94 3.5 (-7.7,14.7) 0.53 
Sticky saliva 8.0 (0.21) -4.0 (-16.1,8.0) 0.51 -8.7 (-20.9,3.5) 0.16 
Coughing 13.6 (0.01) -13.8 (-24.7,-2.9) 0.01 -6.1 (-16.8,4.6) 0.26 
Feeling ill 10.7 (0.05) -13.8 (-24.6,-2.9) 0.01 -10.5 (-20.6,-0.4) 0.04 
Use of pain killers 20.7 (0.03) -16.2 (-38.1,5.7) 0.15 -19.4 (-41.9,3.2) 0.09 
Use of nutritional 
supplements 
19.8 (0.02) -12.8 (-30.3,4.6) 0.15 -21.0 (-38.5,-3.5) 0.02 
Use of feeding tube 9.3 (0.12) -5.4 (-18.0,7.2) 0.40 -6.8 (-19.2,5.5) 0.27 
Weight loss 25.3 (0.01) -27.3 (-47.0,-7.6) 0.01 -25.4 (-47.4,-3.5) 0.02 
Weight gain 5.4 (0.49) 6.6 (-13.1,26.3) 0.51 10.3 (-10.6,31.1) 0.33 
* p<0.05 (significant at this level) 
a 
Negative values for differences favor the intervention group 
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Table 5 Clinically relevant changes (better or worse) in both groups at 6 and at 12 months 
 6 months 12 months 
 improved  deteriorated  improved  deteriorated  
 i-group 
n (%) 
c-group 
n (%) 
i-group 
n (%) 
c-group 
n (%) 
i-group 
n (%) 
c-group 
n (%) 
i-group 
n (%) 
c-group 
n (%) 
PAIS-SR a         
Health Care Orientation   6 (9)   7 (10) 11 (17)   6 (8)   3 (5)   8 (12)   4 (7) 11 (17) 
Vocational environment   4 (6)   1 (1) 17 (26) 11 (15)   1 (2)   4 (6)   9 (15)   7 (11) 
Domestic Environment   6 (9)   8 (11) 10 (16)   6 (8)   3 (5)   7 (11)   6 (10)   9 (14) 
Sexual Relations   5 (8)   2 (3) 11 (18)   2 (3)   4 (7)   2 (3)   7 (12)   5 (8) 
Extended Family 
Relations 
  9 (15) 11 (16)   8 (13)   7 (11)   4 (7)   4 (6)   6 (11) 13 (20) 
Social Environment   9 (14) 14 (20) 27 (41) 13 (15)   8 (13)   7 (11)   8 (14) 12 (18) 
Psychological Distress   6 (9)   8 (11) 16 (25) 11 (16)   6 (10)   8 (12)   8 (14)   9 (14) 
Total Adjustment   7 (11) 11 (15) 23 (35) 17 (24)   5 (8)   8 (12)   9 (15) 15 (23) 
EORTC QLQ-C30 b         
Functional Scales         
Physical functioning 30 (48) 13 (19) 10 (16)   8 (11) 15 (25)   7 (11)   5 (9)   4 (6) 
Role functioning 39 (63) 28 (41) 11 (18) 16 (23) 16 (27) 21 (33) 10 (17) 10 (16) 
Emotional functioning 14 (23) 15 (21) 10 (16) 13 (19)   9 (15) 10 (16)   8 (14) 10 (16) 
Cognitive functioning 20 (32)   9 (13) 13 (22) 11 (16) 13 (22) 12 (19) 10 (17) 12 (19) 
Social functioning 26 (43) 19 (27)   8 (13) 13 (19) 12 (20) 12 (19) 11 )20) 11 (17) 
Global health status/QOL 32 (52) 20 (29)   6 (10) 10 (14) 15 (25) 12 (19)   6 (10) 14 (23) 
EORTC QLQ-C30 b         
Symptom Scales         
Fatigue 42 (68) 34 (49)   6 (10) 22 (31) 22 (37) 23 (36)   9 (16)   9 (14) 
Nausea/vomiting 15 (24)   9 (13)   1 (2)   4 (6)   4 (7)   5 (8)   2 (3)   6 (9) 
Pain 38 (61) 25 (36)   7 (11) 15 (21) 15 (25) 17 (26)   7 (12) 17 (27) 
Dyspnea 19 (31)   6 (9)   6 (10) 13 (19)   5 (8)   9 (14)   5 (9)   8 (13) 
Insomnia 21 (33) 20 (29)   8 (13) 13 (19) 11 (19) 12 (19) 10 (17) 12 (19) 
Appetite loss 23 (51) 13 (19)   5 (8)   9 (13) 11 (19)   6 (9)   3 (6)   7 (11) 
Constipation 19 (31) 11 (16)   5 (8)   6 (9)   9 (15)   4 (6)   3 (5)   5 (8) 
Diarrhea   6 (10)   8 (12)   4 (7)   5 (7)   5 (8)   4 (6)   3 (5)   8 (13) 
Financial difficulties   5 (8)   6 (9)   6 (10)   4 (7)   3 (5)   6 (9)   4 (7)   5 (8) 
EORTC QLQ-H&N35 b         
Symptom scales         
Pain 38 (61) 26 (38)   1 (2)   7 (10)   9 (15)   9 (14)   7 (12)   7 (11) 
Swallowing 35 (56) 25 (36)   7 (11)   9 (13) 13 (22) 10 (16)   5 (9) 11 (17) 
Senses 33 (53) 19 (27)   7 (11) 11 (16) 14 (24) 14 (22)   9 (16) 11 (17) 
Speech 42 (67) 31 (44)   4 (6)   8 (11) 11 (19)   8 (12) 11 (19) 14 (22) 
Social eating 34 (54) 19 (27)   3 (5)   3 (4) 16 (27)   5 (8)   6 (10)   9 (14) 
Social contact 15 (24) 11 (16)   3 (5)   6 (9)   8 (13)   4 (6)   2 (3)   4 (6) 
Less sexuality 21 (34) 10 (14)   7 (12) 10 (15) 11 (21) 10 (19)   8 (16)   5 (9) 
Teeth problems 11 (18) 15 (22) 12 (20)   9 (14) 10 (17) 11 (18)   7 (12)   2 (3) 
Opening mouth 31 (50) 20 (30)   6 (10)   6 (9) 12 (20) 11 (17)   5 (9)   6 (9) 
Dry mouth 22 (35) 20 (29) 12 (19)   6 (9) 12 (20) 15 (23) 10 (17)   7 (11) 
Sticky saliva 27 (44) 23 (33)   7 (11)   9 (13) 11 (19)   9 (14)   6 (11)   9 (14) 
Coughing 26 (42) 16 (24)   8 (13) 13 (20)   4 (7) 11 (17) 11 (19)   8 (13) 
Feeling ill 29 (47) 18 (27)   4 (7)   6 (9)   3 (5)   8 (12)   5 (9)   5 (8) 
Use of pain killers 26 (41) 20 (29)   4 (6)   7 (10)   7 (12)   7 (11)   3 (5)   8 (12) 
Use of nutritional 
supplements 
19 (30)   8 (11)   4 (6)   2 (3) 10 (17)   4 (6)   4 (7)   2 (3) 
Use of feeding tube   9 (14)   4 (6)   2 (3)   0   1 (1)   0   1 (2)   1 (2) 
Weight loss 26 (41) 12 (17)   2 (3)   6 (9)   7 (12)   4 (6)   7 (12)   3 (5) 
Weight gain   5 (8)   8 (12) 11 (19) 12 (18)   7 (12)   6 (9)   9 (16)   5 (8) 
i-group intervention group, c-group comparison group 
Bold figures indicate a difference of ≥10 patients between groups 
a PAIS-SR: figures based on a change of at least one standard deviation  
b EORTC QLQ-C30 & H&N35: Improvement by at least 10 points (better QOL and functioning or fewer symptoms) 
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